ArchiMed buys Stragen Pharma
ArchiMed has acquired a majority stake in Switzerland-based Stragen Pharma, a company that produces generic drugs for complex and life-threatening illnesses.
ArchiMed said in a statement that current CEO Jean-Luc Tétard is to step down from his role following the deal, but will continue to hold a role on the board. Amine Achite, the former CEO of EA Pharma, will take on the role of CEO.
The GP aims to support the company in developing its product portfolio and intends to invest in its existing operations.
The deal is the fourth platform investment from Med Platform I, which held a final close in August 2020 on €1bn, surpassing its €800m target. The vehicle will be two-thirds committed following the deal.
While the GP's Med I and Med II funds focus on small-cap deals, Med Platform I is its largest vehicle raised to date and targets mid-cap healthcare companies valued at more than €100m. The fund can deploy equity tickets of €50-500m and aims to make six platform investments, with the aim of pursuing buy-and-build strategies to double the size of the businesses during the investment period.
Unquote sister publication Mergermarket reported in May 2020 that Stragen Pharma was up for sale, advised by Cantor Fitzgerald. The company generated EBITDA in the €7-10m range and €60-70m in revenues. Sources told Mergermarket that GPs with healthcare experience could look at the business, including Ardian, Gilde Healthcare Partners, Advent International and Apax Partners.
Company
Founded in 1990, Stragen Pharma specialises in the production of generic drugs for complex and life-threatening illnesses, often producing drugs required by patients in intensive care. The company also produces a range of consumer health products and original drugs. Stragen produces 40 products in total, which are sold in around 60 countries.
Stragen posts revenues of €70m and is headquartered in Geneva.
People
Stragen Pharma – Jean-Luc Tétard (founder); Amine Achite (CEO).
ArchiMed – Jean-Yves Desmottes (partner); André-Michel Ballester (managing partner).
More on Buyouts
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Main Capital’s Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
Exponent divests ‘significant' stake in Meadow to Canadian investor
Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater